Commit Biologics Extends Seed Funding by €5.5m with Korys Investment
Deal News | Jan 28, 2025 | Bioqube Ventures NV
Commit Biologics, a biotech company focused on activating the complement system to address cancer and autoimmune diseases, has announced an addition of €5.5 million to its seed financing base, bringing the total to €21.5 million. The extension was led by Korys, a new investor, marking a notable involvement in advancing Commit's innovative BiCE™ platform. This financing is significant for Commit, which had publicly launched just last May, positioning the company for further developments in their therapeutic pursuits.
Sectors
- Biotechnology
- Venture Capital
Geography
- Denmark – Commit Biologics is based in Aarhus, Denmark, highlighting the geographical focus of the article.
- Belgium – Korys is a Belgian investment company, linking the article to Belgium through their financial involvement.
Industry
- Biotechnology – The article discusses Commit Biologics, a company involved in developing biotechnology solutions for cancer and autoimmune diseases.
- Venture Capital – Korys's investment in Commit Biologics indicates engagement in venture capital activities, particularly in the biotechnology sector.
Financials
- €5.5m – An extension to the seed financing for Commit Biologics provided by Korys.
- €21.5m – The total seed financing raised by Commit Biologics since its launch, after the new investment.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Commit Biologics | Target Company | Company | A biotech firm specializing in the complement system for cancer and autoimmune disease treatment. |
| Korys | Investor | Company | A Belgian investment company providing €5.5m in seed financing to Commit Biologics. |